Christopher Wright Biography and Net Worth

Director of Alkermes

Dr. Wright serves as Chief Medical Officer of Wave Life Sciences Ltd., a publicly-traded clinical-stage biotechnology company focused on developing RNA-targeting medicines. Prior to joining Wave, he served as Chief Medical Officer at gene therapy companies Ring Therapeutics (founded by Flagship Pioneering) and AavantiBio, Inc. (acquired by Solid Biosciences Inc.). Prior to those roles, Dr. Wright served as Senior Vice President, Chief Medical Officer of Cyclerion Therapeutics, Inc., where he led global development functions across therapeutic areas, and prior to that, he served as Senior Vice President, Chief Development Officer at Ironwood Pharmaceuticals, Inc. Earlier in his career, Dr. Wright held a variety of medicines development and medical affairs roles at Axcella Health Inc. and Vertex Pharmaceuticals Incorporated, most recently as Senior Vice President of Global Medicines Development and Affairs at Vertex. Dr. Wright was an Associate Professor of Neurology at Harvard Medical School and a board-certified practicing neurologist at Brigham and Women’s Hospital for 20 years.

What is Christopher I. Wright's net worth?: The estimated net worth of Christopher I. Wright is at least $1.14 million as of June 12th, 2026. Dr. Wright owns 25,680 shares of Alkermes stock worth more than $1,137,110 as of June 15th. This net worth evaluation does not reflect any other investments that Dr. Wright may own. Learn More about Christopher I. Wright's net worth.
How do I contact Christopher I. Wright?: The corporate mailing address for Dr. Wright and other Alkermes executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. Alkermes can also be reached via phone at (531) 772-8000 and via email at [email protected]. Learn More on Christopher I. Wright's contact information.
Has Christopher I. Wright been buying or selling shares of Alkermes?: Over the course of the past ninety days, Christopher I. Wright has sold $90,200.00 in Alkermes stock. Most recently, Christopher I. Wright sold 2,000 shares of the business's stock in a transaction on Friday, June 12th. The shares were sold at an average price of $45.10, for a transaction totalling $90,200.00. Following the completion of the sale, the director now directly owns 25,680 shares of the company's stock, valued at $1,158,168. Learn More on Christopher I. Wright's trading history.
Who are Alkermes' active insiders?: Alkermes' insider roster includes Emily Alva (Director), David Anstice (Director), Iain Brown (CFO), Shane Cooke (Director), Wendy Dixon (Director), David Gaffin (SVP), Craig Hopkinson (EVP), Blair Jackson (COO), Michael Landine (SVP), Cato Laurencin (Director), Christian Nichols (SVP), Richard Pops (Chairman & CEO), Christopher Wright (Director), and Nancy Wysenski (Director). Learn More on Alkermes' active insiders.
Are insiders buying or selling shares of Alkermes?: During the last year, insiders at the sold shares 19 times. They sold a total of 218,284 shares worth more than $7,403,451.74. The most recent insider tranaction occured on June, 12th when Director Christopher I Wright sold 2,000 shares worth more than $90,200.00. Insiders at Alkermes own 4.6% of the company. Learn More about insider trades at Alkermes.
Information on this page was last updated on 6/12/2026.

Christopher I. Wright Insider Trading History at Alkermes

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/12/2026	Sell	2,000	$45.10	$90,200.00	25,680

Christopher I. Wright Buying and Selling Activity at Alkermes

Alkermes Company Overview

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Today's Range

Now: $43.53

$43.49

$44.25

50 Day Range

MA: $37.10

$33.02

$44.92

2 Week Range

Now: $43.53

$25.17

$45.76

Volume

219,422 shs

Average Volume

2,208,890 shs

Market Capitalization

$7.25 billion

P/E Ratio

48.40

Dividend Yield

N/A

Beta

0.38